Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
When it comes to the red-hot sector of psychedelics, there’s no shortage of companies looking to enter the market. Quantity over quality can be an issue for any new industry, with hundreds of companies scrambling to stake their claim. However, it appears that a leader has emerged in the field. According to a recent survey by StrawPoll, Denver based Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) ranks as the “favourite” publicly traded company in the psychedelic sector.
This comes as no surprise following Mydecine’s recent landmark progress in psychedelic research across the board. This year has been an important one for the company after successfully completing the first legal import of psychedelic mushrooms to Canada. This marks a major first step in the creation of a comprehensive psychedelic supply chain. In addition to Mydecine’s import capabilities, the company has announced an upcoming clinical trial to study the use of psychedelics in the treatment of PTSD. The first-of-its-kind clinical trial is a major step in the company’s goals to revolutionize the treatment of mental health and wellbeing. These trials are global in scope, with research taking place in 7 countries around the world.
Beyond clinical research and design, Mydecine is also innovating in the world of tech, with the creation of a remote mental health service delivery platform called “Mindleap''. It appears the company has effectively diversified and Mydecine’s CEO, Josh Bartch, attributes their recent success to this diverse set of capabilities.
“One thing about Mydecine that’s incredibly unique is that we’re fully vertically integrated, so as it pertains to psychedelic assisted psychotherapy, we really have an A-Z capability.”
Mydecine is quickly becoming the all-in-one brand in the space of psychedelics. With a recent uplisting to the NEO stock exchange, this novel industry leader has significant potential and will be one to watch moving forward.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes.
